

**FOOD AND DRUG ADMINISTRATION (FDA)**  
**Center for Biologics Evaluation and Research (CBER)**  
**167<sup>th</sup> Meeting of the Vaccines and Related Biological Products**  
**Advisory Committee**  
**September 17, 2021**  
**AGENDA**

**Topic:** The committee will meet in open session to discuss Pfizer-BioNTech’s supplemental Biologics License Application for administration of a third dose, or “booster” dose, of the COVID-19 vaccine, Comirnaty, in individuals 16 years of age and older.

<b>Time</b>	<b>Presentation/Presenter</b>
<b>8:30 a.m.</b>	<p><b><u>Opening Remarks: Call to Order and Welcome (10 min)</u></b>  Arnold Monto, M.D. Acting Chair, VRBPAC  Professor of Public Health and Epidemiology, University of Michigan</p> <p><b><u>Administrative Announcements, Roll Call, Introduction of Committee, Conflict of Interest Statement (20 min)</u></b>  Prabhakara Atreya, Ph.D. Acting Designated Federal Officer, VRBPAC  Director, Division Scientific Advisors and Consultants, CBER, FDA</p>
<b>9:00 a.m.</b>	<p><b><u>FDA Introduction (20 min)</u></b></p> <p><b><u>Welcome</u></b></p> <ul style="list-style-type: none"> <li>• Peter Marks, M.D. Ph.D. Center Director, CBER, FDA</li> </ul> <p><b><u>Introduction of the Topic</u></b></p> <ul style="list-style-type: none"> <li>• Marion Gruber, Ph.D., Director, Office of Vaccines Research and Review (OVR), CBER, FDA</li> </ul> <p><b><u>Background</u></b></p> <ul style="list-style-type: none"> <li>• Ramachandra Naik, Ph.D., Biologist (Regulatory), Division of Vaccines and Related Product Applications (DVRPA), OVR, CBER, FDA</li> <li>• Q/A – 5 Min</li> </ul>
<b>9:20 a.m.</b>	<p><b><u>CDC: Epidemiology of pandemic CDC delta variant/breakthrough infections (15 min)</u></b></p> <ul style="list-style-type: none"> <li>• Sarah Oliver, M.D., M.S.P.H. Centers for Disease Control and Prevention Division of Viral Disease, National Center for Immunization and Respiratory Diseases</li> <li>• Q/A - 5 min</li> </ul> <p><b><u>Real-world effectiveness of COVID-19 vaccines (20 min)</u></b></p> <ul style="list-style-type: none"> <li>• Jonathan Sterne, B.A., M.Sc., Ph.D. Professor of Medical Statistics and Epidemiology Bristol Medical School, University of Bristol, UK</li> <li>• Q/A – 5 min</li> </ul>

**FOOD AND DRUG ADMINISTRATION (FDA)**  
**Center for Biologics Evaluation and Research (CBER)**  
**167<sup>th</sup> Meeting of the Vaccines and Related Biological Products**  
**Advisory Committee**  
**September 17, 2021**  
**AGENDA**

	<p><b><u>Booster protection against confirmed infections and severe disease – data from Israel (30 min)</u></b></p> <ul style="list-style-type: none"> <li>• Speaker 1: Sharon Elroy-Preiss, M.D., M.P.H., M.B.A, Director of Public Health Services, Ministry of Health, Israel</li> <li>• Speaker 2: Ron Milo, Ph.D., Professor, Weizmann Institute, Israel</li> <li>• Q/A – 5 min</li> </ul>
10:40 am	<b><u>BREAK (5 min)</u></b>
10:45 am	<p><b><u>Sponsor Presentation (45 Min)</u></b></p> <p><b>BNT162b2 [COMIRNATY (COVID-19 Vaccine, mRNA)] Booster (Third Dose)</b></p> <ul style="list-style-type: none"> <li>• Donna Boyce, MS, Senior Vice President, Global Regulatory Affairs Pfizer Inc.</li> <li>• William C. Gruber, MD, Senior Vice President, Vaccine Clinical Research and Development Pfizer Inc.</li> </ul>
11:30 am	<p><b><u>FDA Presentation (35 min)</u></b></p> <ul style="list-style-type: none"> <li>• Joohee Lee, M.D., Medical Officer, Clinical Review Branch 1, DVRPA, OVRP, CBER, FDA</li> </ul>
12:05 pm	<b><u>Lunch (25 min)</u></b>
12:30 pm	<b><u>Open Public Hearing (60 min)</u></b>
1:30 pm	<b><u>Break (10 Min)</u></b>
1:40 pm	<b><u>Q &amp; A regarding Sponsor and FDA presentations (45 min)</u></b>
2:25 pm	<b><u>Committee Discussion and Voting (120 min)</u></b>
4:45 pm	<b><u>Meeting Adjourned</u></b>